Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gadodiamide
Drug ID BADD_D00985
Description Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
Indications and Usage For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Marketing Status approved; investigational
ATC Code V08CA03
DrugBank ID DB00225
KEGG ID D04284
MeSH ID C064925
PubChem ID 60754
TTD Drug ID D03EEH
NDC Product Code 0407-0691; 0407-0690; 71806-069
UNII 84F6U3J2R6
Synonyms gadodiamide | Gd-DTPA bis-(methylamide) | Gd-DTPA-BMA | Omniscan | Omniscan Unique Softpack
Chemical Information
Molecular Formula C16H28GdN5O9
CAS Registry Number 122795-43-1
SMILES CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.042680%
Injection site pain12.07.03.011; 08.02.03.0100.007113%Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.035567%
Loss of consciousness17.02.04.0040.054773%Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.004--Not Available
Mental impairment19.21.02.003; 17.03.03.0020.010670%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Movement disorder17.01.02.0100.010670%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.008--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.0080.007113%Not Available
Muscular weakness15.05.06.001; 17.05.03.0050.035567%
Musculoskeletal pain15.03.04.0070.007113%
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.0010.015649%
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.0100.007113%Not Available
Ocular hyperaemia06.04.05.0040.010670%Not Available
Oedema14.05.06.010; 08.01.07.0060.028454%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.014227%
Oral discomfort07.05.05.0010.007113%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.0100.024897%
Pain of skin23.03.03.0030.017783%
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.015649%Not Available
Palpitations02.11.04.0120.029876%
Papule23.03.03.0380.017783%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.032010%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages